Biogen makes a buyout deal, but it’s not the big one you’ve been waiting for
The catalyst junkies have been buzzing for days about the possibility that Biogen would use its Q4 report Thursday to fire off a long anticipated transformational deal. They got a deal today, but it was more of a careful seed move than a market groundbreaker.
Biogen is paying $10 million upfront to buy the XPO1 inhibitor KPT-350 from Karyopharm $KPTI. The drug is designed to guard against neurotoxicity and inflammation in the brain, which could provide some help for the neurodegeneratively focused Biogen’s $BIIIB pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.